European Medicines Evaluation Agency Grants Cell Therapeutics, Inc. (CTIC) Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL) 12/21/2009
More...
|
Cell Therapeutics, Inc. (CTIC) Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 12/17/2009
More...
|
Genmab A/S (GEN.CO) Announces Positive Top-Line Results for Arzerra(tm) in Front Line NHL 8/26/2009
More...
|
Genmab A/S (GEN.CO), GlaxoSmithKline (GSK) (JOBS) Cancer Drug Arzerra Disappoints in Phase 3 Study 8/20/2009
More...
|
FDA Accepts for Review Spectrum Pharmaceuticals, Inc. (SPPI)'s Response on ZEVALIN as a Class 1 Submission, and Establishes September 7, 2009 as Decision Date 7/20/2009
More...
|
Cell Therapeutics, Inc. (CTIC) Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Therapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) 6/22/2009
More...
|
Immunomedics, Inc. (IMMU) Release: Final Therapy and Safety Results From Phase I/II Study of Veltuzumab, a Second-Generation Anti-CD20 Humanized Antibody, Published 5/19/2009
More...
|
Medarex, Inc. (MEDX) Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research 4/20/2009
More...
|
Cell Therapeutics, Inc. (CTIC) (JOBS) Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals, Inc. (SPPI) for $18 Million 2/23/2009
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 12/9/2008
More...
|
Spectrum Pharmaceuticals, Inc. (SPPI) Release: ZEVALIN Consolidation in First-Line Therapy in Patients with Non-Hodgkin’s Lymphoma Resulted in a Progression-Free Survival of Greater Than 67 Months 12/8/2008
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma 11/10/2008
More...
|
Genmab A/S (GNMSF.PK) Recruitment Completed in Ofatumumab NHL Pivotal Study Summary 9/23/2008
More...
|
Micromet's New Antibody Drug Helps Cells Kill Blood Cancer; Clinical Data Show Tumor Regressions In Relapsed Lymphoma Patients Treated With T Cell Engaging BiTE Antibody Blinatumomab 8/15/2008
More...
|
Stanford University School of Medicine Study Finds Tobacco Plant Could Actually Aid Patients with Non-Hodgkin's Lymphoma 7/22/2008
More...
|
Biovest International, Inc. Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial 7/17/2008
More...
|
Innate Pharma Release: IPH 1101 in Combination with Rituximab Authorized to Enter the Second Part of the Phase I/II Trial in Follicular Lymphoma 7/17/2008
More...
|
Celgene International Sárl (CELG) Release: Preliminary Results from International Study Report That REVLIMID(R) Provides Responses for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma 6/16/2008
More...
|
Biovest International, Inc. Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms 6/11/2008
More...
|
Pharmacyclics, Inc. (PCYC) Release: Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 6/5/2008
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 6/5/2008
More...
|
Cytokinetics, Inc. (CYTK) Announces Clinical Trial Data Related to SB-743921 Presented at the 10th International Conference on Malignant Lymphoma 6/5/2008
More...
|
Seattle Genetics, Inc. (SGEN) Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data; Multiple Objective Responses Were Achieved And SGN-40 Was Generally Well Tolerated With No Maximum Tolerated Dose Identified 6/5/2008
More...
|
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 6/5/2008
More...
|
Rigel Pharmaceuticals, Inc. (RIGL) Release: Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL; Results to be Presented at Lymphoma Meeting in Lugano, Switzerland 6/3/2008
More...
|
Rigel Pharmaceuticals, Inc. (RIGL) to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 6/3/2008
More...
|
MethylGene Reports Clinical Data From a Phase II Study Evaluating MGCD0103 in Relapsed or Refractory Non-Hodgkin Lymphomas
6/3/2008
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 6/3/2008
More...
|
Wyeth Pharmaceuticals (Pennsylvania) (WYE) Release: New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma - Data From Phase 3 Study Presented at American Society of Clinical Oncology 6/2/2008
More...
|
Celgene Corporation (CELG) Release: Updated REVLIMID(R) Results Presented In Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) at American Society of Clinical Oncology 6/2/2008
More...
|
Accentia Biopharmaceuticals (ABPI) Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA; Shares Jump 4/17/2008
More...
|
Seattle Genetics, Inc. (SGEN) Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma 4/8/2008
More...
|
Cell Therapeutics, Inc. (CTIC) Announces Enrollment Complete in Phase III EXTEND Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 3/25/2008
More...
|
Cell Therapeutics, Inc. (CTIC) Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 3/17/2008
More...
|
National Cancer Institute Studying Mutations in Non-Hodgkin Lymphoma Yields Clues for Potential New Therapies 3/10/2008
More...
|
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma 2/20/2008
More...
|
FDA Accepts Cephalon, Inc. (CEPH) TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma 2/19/2008
More...
|
Cancer Drug Slows Multiple Sclerosis Progression 2/14/2008
More...
|
InNexus Biotechnology Inc. (IXS) Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin's Lymphoma With Leading Marketed Product 2/8/2008
More...
|
Frost & Sullivan Release: Promising Drugs for Non-Hodgkin’s Lymphoma May Change European Market Dynamics 1/29/2008
More...
|
Cell Therapeutics, Inc. (CTIC) Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma 1/17/2008
More...
|
Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-Hodgkin’s Lymphoma
1/16/2008
More...
|
MethylGene and Pharmion Corporation (PHRM) Start Phase II Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 1/9/2008
More...
|
Seattle Genetics, Inc. (SGEN) Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma 1/8/2008
More...
|
"C" to Believe: Thomas Jefferson University Scientists Studying the Effects of High Dose Vitamin C on Non-Hodgkin Lymphoma Patients 1/3/2008
More...
|
Some Sun May Guard Against Non-Hodgkin's Lymphoma 1/2/2008
More...
|
Cephalon, Inc. (CEPH) Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 12/31/2007
More...
|
Celgene International Sárl (CELG) Two Studies Demonstrate REVLIMID® (lenalidomide) Activity in Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma 12/11/2007
More...
|
Biovest International, Inc. Announces It Has Closed an $8.5M Financing to Support Unblinding and Data Analysis of Fast Tracked Pivotal Phase 3 Study of BiovaxID for Non-Hodgkin's Lymphoma with Public Release of Results Anticipated by April 2008 12/11/2007
More...
|
Pharmacyclics, Inc. (PCYC) Announces Presentation of Results from Phase 1/2 Trial of Xcytrin Plus Zevalin 12/10/2007
More...
|
Enzon Pharmaceuticals, Inc. (ENZN) Presents New PEG-SN38 Preclinical Data at American Society of Hematology 12/10/2007
More...
|
Seattle Genetics, Inc. (SGEN) Initiates SGN-40 Phase IIb Clinical Trial in Combination with Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma 12/7/2007
More...
|
Cephalon, Inc. (CEPH) Announces Positive Treanda Trial Results; Stock Up 10/24/2007
More...
|
Accentia Biopharmaceuticals (ABPI) Announces Unblinding and Analysis of Fast Tracked Phase 3 Trial for BiovaxID 10/16/2007
More...
|
Biovest International, Inc. Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma 10/16/2007
More...
|
InNexus Biotechnology Inc. (IXS) to Host Teleconference/Web Cast Outlining Recently Launched Pre-Clinical Candidate DXL625 (CD20) 8/9/2007
More...
|
Based on Up to 6 Years of Follow-Up, Biovest International, Inc. Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 6/28/2007
More...
|
National Comprehensive Cancer Network Updates Non-Hodgkin's Lymphoma Guidelines 6/20/2007
More...
|
Genmab A/S (GNMSF.PK) Says Ofatumumab Successful Against Rheumatoid Arthritis in Phase 2 Trial 6/15/2007
More...
|
GlaxoSmithKline (GSK) Announces Phase II Data of a Single One-Week Course of Frontline Treatment with the BEXXAR(R) Therapeutic Regimen 6/5/2007
More...
|
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients 6/4/2007
More...
|
Favrille, Inc. (FVRL) Reports Status of Phase 2 Clinical Trial of FavId With Maintenance Rituxan for Indolent B-Cell Non-Hodgkin's Lymphoma 6/4/2007
More...
|
Allos Therapeutics, Inc. (ALTH) Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease 6/1/2007
More...
|
Genitope Corporation (GTOP) Initiates Clinical Trial to Evaluate Use of MyVax(R) Personalized Immunotherapy Following Treatment With Rituximab and Chemotherapy for Follicular Non-Hodgkin's Lymphoma 5/21/2007
More...
|
Cell Therapeutics, Inc. (CTIC) Receives FDA Special Protocol Assessment (SPA) Comments on the Design of Phase III Trial of Pixantrone in Relapsed Indolent NHL 5/17/2007
More...
|
Dr. Reddy's Laboratories, Inc. (RDY) launches Reditux(TM) - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma 4/30/2007
More...
|
ProNAi Therapeutics, Inc. Announces Preclinical Success for PNT2258 Therapeutic - Curative Events in Xenograft Mice for Difficult-to-Treat Non-Hodgkin's Lymphoma 4/17/2007
More...
|
Genentech, Inc. (DNA) And Seattle Genetics, Inc. (SGEN) Announce Exclusive Global Licensing Agreement For Development And Commercialization Of SGN-40; Seattle Genetics To Receive Upfront $60M 1/8/2007
More...
|
Seattle Genetics, Inc. (SGEN) Initiates Phase II Clinical Trial Of SGN-40 For The Treatment Of Non-Hodgkin’s Lymphoma 12/20/2006
More...
|
Seattle Genetics, Inc. (SGEN) Announces Advancements In Development Programs At American Society of Hematology Meeting 12/12/2006
More...
|
Immunomedics, Inc. (IMMU) Release: Low Doses Of Humanized Anti-Cd20 Antibody Reported Active In Non-Hodgkin's Lymphoma 12/11/2006
More...
|
Favrille, Inc. (FVRL) Announces Interim Analysis Of Secondary Endpoint From Pivotal Phase 3 Clinical Trial Of FavId Following Rituxan In Follicular B-Cell Non-Hodgkin's Lymphoma; Drug Misses Secondary Target 11/13/2006
More...
|
New Landmark Study Shows The Use Of Accentia Biopharmaceuticals (ABPI)' BiovaxID Formulation Improves Disease Free Survival In 80% Of Patients Whose Cancer Has Relapsed After Chemotherapy Administered With Or Without Rituxan 10/20/2006
More...
|
Accentia Biopharmaceuticals Majority-Owned Subsidiary Biovest International, Inc. Receives Rare Disease Designation From European Drug Agency For Follicular Non-Hodgkin's Lymphoma 10/11/2006
More...
|
FDA Grants Priority Review To Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM)'s VELCADE(R) (Bortezomib) For Injection For Treatment Of Relapsed Mantle Cell Lymphoma 8/9/2006
More...
|
Cell Therapeutics, Inc. (CTIC) Announces Encouraging Pixantrone Phase III Interim Data; Trial Will Continue 8/8/2006
More...
|
Genitope Corporation (GTOP) Release: Data Safety Monitoring Board Recommends Continuation Of MyVax(R) Personalized Immunotherapy Phase 3 Trial After Second Interim Analysis; Shares Plummet 7/28/2006
More...
|
ZymoGenetics, Inc. (ZGEN) Begins Phase 1 Trial With IL-21 and Rituxan(R) In Patients With Non-Hodgkin's Lymphoma 7/12/2006
More...
|
Genmab A/S (GNMSF.PK) Initiates Ofatumumab (Humax-Cd20) Pivotal Study In NHL 7/10/2006
More...
|
Favrille, Inc. (FVRL) Publishes Data From Phase 2 Clinical Trial Demonstrating Biologic Activity Of Lead Product Candidate FavId In Indolent Non-Hodgkin's Lymphoma 7/5/2006
More...
|
Micromet Release: Preliminary Clinical Data Of MT103 (MEDI-538), A CD19-specific BiTE®, Indicate Biological And Clinical Activity In Non-Hodgkin Lymphoma 6/19/2006
More...
|
Biovest International, Inc. To Expand BiovaxID Phase 3 Trial In Ukraine And Russia; Regulatory Documents Filed 6/6/2006
More...
|
Immunomedics, Inc. (IMMU) Release: Humanized Anti-CD20 Antibody Appears Safe And Active In Non-Hodgkin's Lymphoma In Phase I/II Study 6/5/2006
More...
|
Eli Lilly and Company (LLY) Launches Phase III Trial Of Once-Daily, Targeted Oral Cancer Agent 5/31/2006
More...
|
The Leukemia & Lymphoma Society Release: Researchers Identify Genetic Defects That Cause Main Types Of Non-Hodgkin Lymphoma, Paving The Way For Potential New Targeted Therapies 5/26/2006
More...
|
FDA Gives Permission To Use Very Sensitive Molecular Evidence Of Cancer In BiovaxID Pivotal Phase 3: Company Intends To Use Blood Test To File Application For Accelerated Approval 5/16/2006
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Pixantrone Produces High Rate (77 Percent) Of Complete Tumor Disappearance In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma 5/16/2006
More...
|
Genitope Corporation (GTOP) To Present Phase 2 Clinical Trial Data At American Society of Clinical Oncology Annual Meeting 5/2/2006
More...
|
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) And Johnson And Johnson and Johnson Pharmaceutical Research and Development, LLC Initiate Phase III Clinical Trial With VELCADE(R) For Injection In Follicular Non-Hodgkin's Lymphoma 4/18/2006
More...
|
Scientists Discover New Genetic Subtypes Of Common Blood Cancer 4/10/2006
More...
|
Enzon Pharmaceuticals, Inc. (ENZN) Initiates Clinical Program For ONCASPAR(R) 4/4/2006
More...
|
Genentech, Inc. (DNA) And Biogen Idec, Inc. (Massachusetts) (BIIB) Submit Supplemental Biologics License Application For First-Line Use Of Rituxan(R) In Low-Grade Or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma 3/30/2006
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Pixantrone Combination Regimen Produces High Rates Of Complete Remission For Patients With Aggressive NHL Who Fail CHOP Therapy 3/22/2006
More...
|
Biovest International, Inc. Submits Amendment Request To FDA For Use Of Molecular Remission Data In The Ongoing Pivotal Phase 3 Study To Support Accelerated, Conditional Approval Of BiovaxID (TM) 2/22/2006
More...
|
Scheduled Combination Of Allos Therapeutics, Inc. (ALTH)' Pralatrexate Plus Gemcitabine Proves Superior To Methotrexate Plus Cytarabine In Models Of Human Non-Hodgkin's Lymphoma 2/14/2006
More...
|
Genentech, Inc. (DNA) Release: First FDA-Approved Treatment To Improve Survival For Patients With The Aggressive Form Of Non-Hodgkin's Lymphoma In More Than 25 Years 2/13/2006
More...
|
Favrille, Inc. (FVRL) Completes Patient Enrollment In Pivotal Phase 3 Clinical Trial Of FavId For Follicular B-Cell Non-Hodgkin's Lymphoma 1/30/2006
More...
|
Biovest International, Inc. Release: BiovaxID(TM) Yields 89% Survival In Patients With Aggressive Non-Hodgkins Mantle Cell Lymphoma At Median Follow-up Of 3.8 Years 1/24/2006
More...
|
Favrille, Inc. (FVRL) Receives FDA Fast Track Designation For FavId, Lead Product Candidate For Follicular B-Cell Non-Hodgkin's Lymphoma; Stocks Soar 1/12/2006
More...
|
Tanox, Inc. (TNOX) Submits Investigational New Drug Application For TNX-650 For Treatment Of Hodgkin's Lymphoma 12/20/2005
More...
|
Favrille, Inc. (FVRL) Reports Positive Data From Phase 2 Clinical Trial Of FavId Following Rituxan At American Society of Hematology Annual Meeting 12/13/2005
More...
|
Cougar Biotechnology Announces Presentation Of Positive Preclinical Data Or CB3304 In Non-Hodgkin's Lymphoma And Multiple Myeloma 12/13/2005
More...
|
Pharmacyclics, Inc. (PCYC) Announces Presentation And Publication Of Preliminary Results Evaluating Xcytrin For The Treatment Of Refractory B-cell Lymphomas 12/12/2005
More...
|
Cephalon, Inc. (CEPH) Oncology Reports High Response Rates To Single Agent TREANDA In Non- Hodgkin's Lymphoma 12/12/2005
More...
|
American Society of Hematology Release: Advances In Radiotherapy Show Benefit For High-Risk Elderly Patients With Leukemia And Non-Hodgkin Lymphoma 12/12/2005
More...
|
Eli Lilly and Company (LLY) Release: Investigational Targeted Therapy May Offer Progress For Non-Hodgkin's Lymphoma Patients 12/12/2005
More...
|
Cougar Biotechnology Announces Positive Interim Results From Phase I Trial For CB3304 (Noscapine) In Non-Hodgkin's Lymphoma 12/12/2005
More...
|
Immunomedics, Inc. (IMMU) Reports Humanized Anti-CD20 Antibody Appears Safe And Active In Non-Hodgkin's Lymphoma 12/12/2005
More...
|
Scientific Advances On Three Lead Cephalon, Inc. (CEPH) Oncology Compounds To be Presented At 47th American Society of Hematology Meeting 12/8/2005
More...
|
Expert From The Leukemia & Lymphoma Society Available To Comment On Presentations From Annual American Society of Hematology Conference 12/6/2005
More...
|
Genmab A/S (GNMSF.PK) Announces Data On All Evaluable Patients In HuMax(R)-CD20 NHL Phase I/II Study 12/1/2005
More...
|
Favrille, Inc. (FVRL) Announces New Data From Phase 2 Clinical Trial Of FavId Following Rituxan In Patients With Follicular B-Cell Non-Hodgkin's Lymphoma 11/16/2005
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) And Genentech, Inc. (DNA) Cancer Drug Helps Arthritis 11/14/2005
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Addition Of Pixantrone To Rituxan(R) Therapy Significantly Prolongs Time To Disease Progression And Improves The Overall Response Rate Compared To Rituxan Alone In Relapsed Or Refractory Indolent Lymphoma 11/9/2005
More...
|
Roche (RHHBY) Says MabThera Gets Positive Phase III Data 10/26/2005
More...
|
Genentech, Inc. (DNA) And Biogen Idec, Inc. (Massachusetts) (BIIB): FDA Grants Priority Review For Rituxan(R) Supplemental Biologics License Application For Front-Line Treatment Of Intermediate-Grade Or Aggressive Non-Hodgkin's Lymphoma 10/25/2005
More...
|
Praecis Pharmaceuticals Incorporated (PRCS) Presents Preclinical Data On PPI-2458 9/21/2005
More...
|
MDS Nordion (MDZ) Supplies Yttrium-90 For ZEVALIN, Novel Radioimmunotherapy For Non-Hodgkin's Lymphoma 9/20/2005
More...
|
Genentech, Inc. (DNA) And Biogen Idec, Inc. (Massachusetts) (BIIB) File Supplemental Biologics License Application For FDA Review Of Rituxan(R) For Front-Line Treatment Of Intermediate Grade Or Aggressive CD-20-Positive, B-Cell, Non-Hodgkin's Lymphoma 8/17/2005
More...
|
Preclinical Study Supports Therapeutic Potential Of Micromet's Drug Candidate MT103 8/1/2005
More...
|
New Drug From Human Genome Sciences: Investment Potential? 7/6/2005
More...
|
Favrille, Inc. (FVRL) To Report Data From Two Phase II Clinical Trials At The 2005 Pan Pacific Lymphoma Conference 7/1/2005
More...
|
Human Genome Sciences, Inc. (HGSI) Reports Interim Results Of Phase 2 Clinical Trial Of HGS-ETR1 In Patients With Advanced Non-Hodgkin's Lymphoma 6/13/2005
More...
|
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) Release: VELCADE(R) (bortezomib) For Injection Showed Positive Activity Across A Variety Of Lymphomas 6/13/2005
More...
|
Genta Incorporated (GNTA) Release: Genasense(R) Plus Rituximab Reported Active In Patients With Relapsed Non-Hodgkin's Lymphoma 6/13/2005
More...
|
Alcohol Seems To Lower Risk Of Non-Hodgkin Lymphoma 6/7/2005
More...
|
Favrille, Inc. (FVRL) Announces Initiation Of Phase II Clinical Trial In Europe 6/7/2005
More...
|
Favrille, Inc. (FVRL) Reports Data From Phase II Clinical Trial 6/2/2005
More...
|
Genmab A/S (GNMSF.PK) Release: HuMax(R)-CD20 Effective In Killing Tumor Cells With Very Low Levels Of CD20 6/2/2005
More...
|
European Regulatory Committee Recommends Orphan Drug Status For GPC Biotech AG's (GPCG.DE) Anticancer Monoclonal Antibody 1D09C3 For Hodgkin's Lymphoma 6/2/2005
More...
|
Favrille, Inc. (FVRL) Announces Status Of Patient Enrollment In Phase III Registration Trial 6/1/2005
More...
|
Human Genome Sciences, Inc. (HGSI) Reports On Progress Toward Commercialization 5/26/2005
More...
|
Genitope Corporation (GTOP) Signs Leases For New Commercial Manufacturing Facility And Corporate Headquarters 5/23/2005
More...
|
INEX Pharmaceuticals (IEX.TO) Presents Marqibo(TM) Clinical Data At Medical Meetings 5/18/2005
More...
|
MethylGene Discloses Preliminary MGCD0103 "An Oral HDAC Inhibitor" Phase I Clinical Data At American Society of Clinical Oncology-Interim Results Reported For Ongoing Clinical Trials 5/16/2005
More...
|
GlaxoSmithKline (GSK) Release: New Analysis Shows Earlier Use Of BEXXAR May Improve Treatment Outcomes In Non-Hodgkin's Lymphoma Patients 5/16/2005
More...
|
Cephalon (CEPH) Announces Acquisition Of Salmedix, Inc.; Approximately $160 Million Cash 5/13/2005
More...
|
Favrille, Inc. (FVRL) Announces Phase 2 Clinical Trial Results For FavId(R) Following Autologous Stem Cell Transplantation To Be Presented During American Society of Clinical Oncology 5/10/2005
More...
|
Micromet's Drug Candidate MT103 Triggers Serial Killing Of Cancer Cells 5/9/2005
More...
|
Favrille, Inc. (FVRL) CEO To Present At Bear Stearns London Healthcare Conference 5/9/2005
More...
|
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) Release: VELCADE(R) (bortezomib) For Injection Phase II Clinical Trial Initiated In Lung Cancer 4/25/2005
More...
|
Novacea Begins Phase 1/2 Trial of Anti-Cancer Agent Banoxantrone (AQ4N) In Patients With Lymphoma 4/20/2005
More...
|
Praecis Pharmaceuticals Incorporated (PRCS) Provides Update On Marketing Authorization Application For Plenaxis In Germany 3/25/2005
More...
|
Spectrum Pharmaceuticals, Inc. (SPPI) To Present At SG Cowen & Co., LLC 25th Annual Health Care Conference 3/11/2005
More...
|
Human Genome Sciences, Inc. (HGSI) Completes Patient Enrollment In A Phase 2 Clinical Trial Of HGS-ETR1 For The Treatment Of Non-Hodgkin's Lymphoma 3/3/2005
More...
|
Spectrum Pharmaceuticals, Inc. (SPPI) To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/22/2005
More...
|
Xcyte Therapies, Inc. Presents Results Of Two Clinical Trials Of Xcellerated T Cells At Tandem BMT Meetings 2/14/2005
More...
|
Lymphoma Treatment Shows Promise 2/3/2005
More...
|
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) Release: VELCADE(R) (Bortezomib) For Injection Shows Promising Activity In Two Phase II Studies Of Patients With Non-Hodgkin's Lymphoma 2/1/2005
More...
|
GPC Biotech AG (GPCG.DE) Announces Initiation Of Phase 1 Human Clinical Trial With 1D09C3 Anticancer Monoclonal Antibody 2/1/2005
More...
|
Genitope Corporation (GTOP) Adds To Operating Management Team 1/27/2005
More...
|
AnorMED (AOM.TO) Announces Patient Enrollment Into Pivotal Phase III Trials For New Stem Cell Transplant Drug Candidate 1/25/2005
More...
|
INEX Pharmaceuticals (IEX.TO) Release: FDA Issues Not Approvable Letter For Marqibo(TM) 1/19/2005
More...
|
Spectrum Pharmaceuticals (SPPI) Receives Notice Of A New U.S. Patent Allowance For EOquin(TM) 1/18/2005
More...
|
Ligand Pharmaceuticals Inc. (LGND) Exercises First Option To Buy Down ONTAK Royalties 1/7/2005
More...
|
GlaxoSmithKline (GSK) Announces Expanded Indication For BEXXAR In Non-Hodgkin's Lymphoma 1/3/2005
More...
|
Genitope Corporation (GTOP) Announces Closing Of $60 Million Private Placement Of Common Stock 12/27/2004
More...
|
Cell Therapeutics, Inc. (CTIC) And Quintiles PharmaBio Development Enter Into TRISENOX(R) Financing Agreement 12/21/2004
More...
|
Genmab A/S' (GNMSF.PK) HuMax-CD20 To Treat CLL Awarded Fast Track Status From FDA 12/16/2004
More...
|
Corixa Corporation (CRXA) Announces Sale And Transfer Of BEXXAR Development And Marketing Rights To GlaxoSmithKline (GSK); Corixa To Focus On Adjuvant Commercialization And TLR4 Agonist/Antagonist Product Development; Restructuring Expected To Result In More Than 50 Percent Reduction In Cash Burn 12/14/2004
More...
|
GlaxoSmithKline (GSK) Acquires Full Marketing And Development Rights For BEXXAR Worldwide 12/14/2004
More...
|
MorphoSys AG Generated Antibody Approved To Enter Clinical Trials 12/9/2004
More...
|
Pharmacyclics, Inc. (PCYC) Release: Results From Phase 1 Trial Of Single Agent Xcytrin For The Treatment Of Refractory Chronic Lymphocytic Leukemia Indicate Anti-Tumor Activity 12/7/2004
More...
|
Millennium Pharmaceuticals, Inc. Release: VELCADE(R) (bortezomib) For Injection Continues To Provide Responses In Several Subtypes Of Non-Hodgkin's Lymphoma 12/7/2004
More...
|
Ligand Pharmaceuticals Inc. (LGND) Release: Abstracts Demonstrate That ONTAK May Benefit Patients With Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma And B-Cell Chronic Lymphocytic Leukemia 12/7/2004
More...
|
Spectrum Pharmaceuticals (SPPI) To Hold The First Annual Investor And Analyst Day On December 9, 2004 12/7/2004
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Phase I/II Experience Of Pixantrone CHOP-Variant (CPOP) Produces Responses In 70 Percent Of Relapsed Aggressive Non-Hodgkin's Lymphoma Patients Who Previously Failed CHOP Chemotherapy 12/6/2004
More...
|
Medarex, Inc. (MEDX) Release: Announces Complete And Partial Responses Observed In Clinical Study Of MDX-060 At American Society of Hematology (ASH) Meeting 12/6/2004
More...
|
Genta Incorporated (GNTA) Release: Ganite(R) Activity In Patients With Advanced Non-Hodgkin's Lymphoma Presented at American Society of Hematology (ASH) Meeting 12/6/2004
More...
|
Genmab A/S's (GNMSF.PK) HuMax-CD20 Shows Favorable Clinical Responses In NHL 12/6/2004
More...
|
Point Therapeutics Reports Results Of Phase 1 Study Of Talabostat In Non-Hodgkin's Lymphoma At The Meeting Of The American Society of Hematology (ASH) 12/6/2004
More...
|
Genta Incorporated (GNTA) Release: Genasense(R) Shown To Enhance The Anti-Lymphoma Activity Of Velcade(R) And Rituxan(R) 12/6/2004
More...
|
American Society of Hematology (ASH) Release: Genetic Target Found For Lymphoma Treatment 12/6/2004
More...
|
INEX Pharmaceuticals (IEX.TO) And Enzon Pharmaceuticals, Inc. (ENZN) Announce ODAC Does Not Support Accelerated Approval For Cancer Drug MARQIBO 12/2/2004
More...
|
AnorMED (AOM.TO) Receives FDA Response To Special Protocol Assessment And Initiates Pivotal Phase III Program For New Stem Cell Transplant Drug Candidate 12/2/2004
More...
|
Seattle Genetics, Inc. (SGEN) Expands SGN-40 Clinical Program Into Non-Hodgkin's Lymphoma 12/2/2004
More...
|
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) Release: New Data On VELCADE(R) (bortezomib) For Injection To Be Presented At Upcoming American Society of Hematology (ASH) 12/1/2004
More...
|
AnorMED (AOM.TO) Evaluates New Stem Cell Transplantation Drug Candidate As Single Agent In Multiple Myeloma Patients And As Combination Regimen In Patients With Hodgkin's disease 12/1/2004
More...
|
Celgene Corporation (CELG) Release: 113 Abstracts On Recent Clinical Data For Thalomid(R), Revlimid(TM), Actimid(TM) And Alkeran(R) To Be Presented At The American Society of Hematology (ASH) 46th Annual Meeting 11/30/2004
More...
|
FDA Briefing Documents Posted For MARQIBO(TM) For Oncologic Drug Advisory Committee Meeting 11/30/2004
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Arsenic Trioxide And Pixantrone Highlighted In 42 Abstracts And Presentations At The American Society of Hematology (ASH) Meeting 11/23/2004
More...
|
Genitope Corporation (GTOP) Provides Update On Progress Of Lead Product Candidate 11/17/2004
More...
|
Spectrum Pharmaceuticals (SPPI) To Present Encouraging Efficacy And Safety Data From The Ongoing Multi-Center Phase 2 Trial Of EOquin In Refractory Superficial Bladder Cancer At The Chemotherapy Foundation Symposium In New York 11/11/2004
More...
|
Enzon, Inc. (ENZN) And INEX Pharmaceuticals (IEX.TO) Announce Filing Of New Drug Submission To Health Canada 11/5/2004
More...
|
Genmab A/S (GNMSF.PK) To Present Data From Phase I/II HuMax-CD20 Study At American Society of Hematology (ASH) Conference 11/5/2004
More...
|
Allergy Link To Blood Cancer Risk 11/4/2004
More...
|
AnorMED (AOM.TO) Expands AMD3100 Stem Cell Transplant Program In Cancer Patients To Include Canada And The European Union 11/4/2004
More...
|
Millennium Pharmaceuticals, Inc. (MLNM) Release: FDA Grants VELCADE(R) (bortezomib) For Injection Fast Track Status For Relapsed And Refractory Mantle Cell Lymphoma 11/3/2004
More...
|
Genentech, Inc. (DNA) , Biogen Idec, Inc. (Massachusetts) (BIIB) And Roche (RHHBY) Release: Preliminary Phase IIB Data Show Rituxan(R) Improved Symptoms In Patients With Moderate-To-Severe Rheumatoid Arthritis 11/2/2004
More...
|
Human Genome Sciences (HGSI) Begins Dosing Of Patients In A Phase 2 Clinical Trial Of HGS-ETR1 In Non-Hodgkin's Lymphoma 10/13/2004
More...
|
Genentech, Inc. (DNA) Receives Subpoena On Rituxan(R) 10/5/2004
More...
|
ZymoGenetics (ZGEN) And Serono (SRA) To Begin TACI-Ig Clinical Studies In B-Cell Malignancies 10/4/2004
More...
|
Human Genome Sciences (HGSI) Reports Results Of Ongoing Phase 1 Clinical Trials Of HGS-ETR1 In Patients With Advanced Cancers 9/29/2004
More...
|
INEX Pharmaceuticals (IEX.TO) And Enzon (ENZN) Announce Marqibo To Be Reviewed By FDA's Oncologic Drugs Advisory Committee 9/27/2004
More...
|
Seattle Genetics, Inc. (SGEN) Initiates SGN-30 Phase II Clinical Trial For Cutaneous Lymphoma 9/23/2004
More...
|
Corixa (CRXA) And GlaxoSmithKline (GSK) Announce FDA Acceptance Of Supplemental Biologics License Application For Expanded Use Of BEXXAR; FDA Response Expected By January 2005 9/20/2004
More...
|
Monkey Virus Exposure Did Not Raise Lymphoma Risk 9/15/2004
More...
|
AnorMED (AOM.TO) To Advance AMD3100 To Phase III Program For Stem Cell Transplant In Cancer Patients 9/13/2004
More...
|
Seattle Genetics, Inc. (SGEN) Receives Orphan Drug Designation For SGN-40 In Multiple Myeloma 8/24/2004
More...
|
Spectrum Pharmaceuticals (SPPI) Announces Submission Of Initial Positive Clinical Results From Ongoing Phase 2 Trial Of Elsamitrucin In Refractory Non-Hodgkin's Lymphoma To The American Society of Hematology (ASH) Annual Meeting 8/11/2004
More...
|